In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region.
ECDC conducted a systematic review of the literature published between 2005–2015, with the aim to estimate the prevalence of hepatitis B and C in the general population and specific population subgroups in the EU/EEA Member States. This review is an update of an earlier review covering the period 2000–2009.
On 31 August 2016 the autonomous Community of Madrid, Spain, reported two cases of infection with Crimean–Congo haemorrhagic fever (CCHF) virus. This document assesses the risk associated with the occurrence of two cases of Crimean–Congo haemorrhagic fever in Spain.
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Following a request by the Romanian government, ECDC conducted a second follow-up country visit to Romania covering HIV, sexually transmitted infections (STIs) and hepatitis B and C from 11–13 May 2011.
Following a request by the Estonian government, ECDC performed a follow-up country visit to Estonia covering HIV and sexually transmitted infections (STIs) from 11–13 October 2010.